{"id":8729,"date":"2025-03-18T11:18:00","date_gmt":"2025-03-18T11:18:00","guid":{"rendered":"https:\/\/ibsal.es\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/"},"modified":"2025-03-18T12:12:21","modified_gmt":"2025-03-18T12:12:21","slug":"a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors","status":"publish","type":"post","link":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/","title":{"rendered":"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors."},"content":{"rendered":"\n<p><strong>The Cardiovascular Pharmacology Group, coordinated by M\u00f3nica Garc\u00eda Domingo, has demonstrated that the serotonergic system contributes differently in female and male rats when it comes to regulating vascular function, which will facilitate differential pharmacological strategies according to sex in cardiovascular pathologies with marked sympathetic hyperactivity, such as arterial hypertension, diabetes or metabolic syndrome<\/strong>.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>The study, published in the high-impact British Journal of Pharmacology, reinforces the need to strengthen research in preclinical animal models to determine how treatments for cardiovascular diseases should be implemented depending on gender, taking into account that they are the leading cause of mortality in women.<\/strong><\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>Researchers from the <a href=\"https:\/\/ibsal.es\/en\/\">Institute of Biomedical Research of Salamanca<\/a> (IBSAL) and the <a href=\"https:\/\/www.usal.es\/\">University of Salamanca<\/a> (USAL) demonstrate that <strong>serotonin (5-HT) contributes differently in female and male rats in regulating vascular function<\/strong>, which opens the way to <strong>new differential pharmacological strategies according to sex in cardiovascular pathologies<\/strong> with marked sympathetic hyperactivity, such as hypertension or diabetes.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>The importance of the study, published in the high-impact <strong><em>British Journal of Pharmacology<\/em>,<\/strong> lies in the fact that these differences not only reinforce the idea that sex affects cardiovascular pathophysiology, but also unmask <strong>the therapeutic potential of acting on different serotonin receptors, personalized according to sex,<\/strong> to maximize effectiveness and reduce risks.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>As explained by  <strong><a href=\"https:\/\/ibsal.portalinvestigacion.com\/investigadores\/1013\">M\u00f3nica Garc\u00eda Domingo<\/a>, coordinator of the <a href=\"https:\/\/ibsal.portalinvestigacion.com\/grupos\/88\">Cardiovascular Pharmacology Group of IBSAL<\/a><\/strong>Although serotonin is best known for its actions in the central nervous system and because it is involved in diseases such as anxiety, depression or eating disorders, we have been studying its role at the peripheral and cardiovascular levels for many years with the aim of finding new therapeutic targets for the treatment of these diseases.  <strong>cardiovascular diseases, which are the leading cause of death worldwide.<\/strong>and although last year in Spain they were surpassed by tumors in men, in women they remain the main cause of death&#8221;.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>Sexual variations in cardiovascular disease are caused in part by environmental\/social differences between men and women, but there are also biological factors that can be studied in animal models, including the sympathetic nervous system, which is related to the development of hypertension or heart failure. Similarly, men and women show different concentrations of serotonin and expression of several of its receptors. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>&#8220;The sympathetic nervous system regulates blood pressure and it has been seen that in cardiovascular pathologies, such as hypertension or diabetes mellitus, there is an increase in this nervous activity. <strong>We are studying how serotonin, through its receptors, is capable of modulating this sympathetic system in order to search for new therapeutic targets in cardiovascular pathologies<\/strong>,&#8221; says the researcher, taking into account the wide variety of serotonin receptors that have been identified to date, each with a specific distribution and function.<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>The researchers, who also belong to the Recognized Research Group (RGRI), have been working on the following topics <em><a href=\"https:\/\/produccioncientifica.usal.es\/grupos\/3797\/detalle\">Serotonergic system and its pharmacological involvement in cardiovascular pathologies<\/a><\/em>The researchers, who also belong to the Recognized Research Group (GIR) of the University of Salamanca, <strong>had already demonstrated in male rats that serotonin is capable of modulating the sympathetic system<\/strong>, both in a normal situation and in pathological situations induced by <strong>hypertension and diabetes<\/strong>. &#8220;And not only at the vascular level, but also in different organs\/tissues, such as the mesentery or the kidney, which contribute to the regulation of blood pressure,&#8221; adds M\u00f3nica Garc\u00eda Domingo. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<h4 class=\"wp-block-heading\" id=\"h-en-ratas-hembras-se-modifican-los-receptores-implicados\"><strong>In female rats, the receptors involved are modified.<\/strong><\/h4>\n\n<p>In the study now published, and with the aim of contributing to a better approach to cardiovascular disease in women, they used female rats of childbearing age (14-16 weeks) and found that serotonin, <strong>as in males, is capable of modulating sympathetic neurotransmission, but the receptors involved are modified.<\/strong><\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>&#8220;Serotonin exerts an inhibitory action on vascular sympathetic activity through the 5-HT1D receptor in the case of females, whereas 5-HT1A was also involved in the case of males. Therefore, we would have to look for <strong>a pharmacological target that would act directly on this receptor<\/strong> and not on the other to reduce sympathetic discharge at the vascular level and prevent the appearance of cardiovascular pathologies,&#8221; he explains. But it has also been shown that in females there are other receptors (5-HT2A and 5-HT3) that enhance sympathetic activity, so <strong>&#8220;in this case the pharmacological interest would be to block them&#8221;.<\/strong>  <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>&#8220;We already have a pharmacological model with which we have blocked the 5-HT2 receptor and we have seen that we favor actions that inhibit the release of noradrenaline with beneficial effects in pathologies such as diabetes. Our next step is to continue working on female rats with induced cardiovascular pathologies and see how they respond,&#8221; says the researcher. They already have pre-established models for working on diabetes and hypertension, and now the objective is to incorporate metabolic syndrome into these experiments. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>In conclusion, the results of this study add to the scientific evidence indicating that <strong>cardiovascular homeostasis is highly sex-dependent and reinforce the need for preclinical pharmacological studies in<\/strong> both female and male <strong>animal models<\/strong> to determine how treatments for cardiovascular disease should be implemented in patients depending on sex. In this case, it has been shown that acting on different serotonin receptors may become a new strategy to treat cardiovascular disorders prevalent in women, which are clearly linked to alterations in the sympathetic nervous system. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<h4 class=\"wp-block-heading\" id=\"h-un-modelo-original-de-experimentacion-animal\"><strong>An original model of animal experimentation<\/strong><\/h4>\n\n<p>The Cardiovascular Pharmacology Group at IBSAL is one of the few in the world, together with the Center for Research and Advanced Studies of the National Polytechnic Institute (CINVESTAV) in Mexico, that uses this <em>in vivo<\/em> methodology to study the serotonergic system and its influence at the cardiovascular level. This international collaboration has led to several joint publications and highlights the importance of continuing to experiment with animal models. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>&#8220;We are currently one of the few groups in which all members are accredited to work with experimental animals and we continue to work <em>in vivo<\/em> on whole animals, tests necessary to facilitate the passage to the clinic. We assess the effects on the whole organism and how it is able to compensate or regulate the whole pharmacological action, which is not possible with other techniques such as isolated organ and cell lines&#8221;, explains the IBSAL scientist, who also shows her willingness to initiate collaborations with the Hospital de Salamanca to promote translational research in the field of experimentation of new drugs for the treatment of different pathologies. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<figure class=\"wp-block-image size-large\"><img fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"683\" src=\"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-1-1024x683.jpg\" alt=\"\" class=\"wp-image-8270\" srcset=\"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-1-1024x683.jpg 1024w, https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-1-300x200.jpg 300w, https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-1-768x512.jpg 768w, https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-1-1536x1024.jpg 1536w, https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-1-2048x1365.jpg 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n<p><sup>From left to right: Asunci\u00f3n Mor\u00e1n, Juan Francisco Fern\u00e1ndez Gonz\u00e1lez, M\u00f3nica Garc\u00eda Domingo, Ana\u00eds Terol \u00dabeda, Mar\u00eda Luisa Mart\u00edn and Jos\u00e9 \u00c1ngel Garc\u00eda Pedraza, in the Pharmacology laboratory of the Faculty of Pharmacy of the University of Salamanca.<\/sup><\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>Reference article:<\/strong><\/p>\n\n<p>Terol-\u00dabeda, AC, Fern\u00e1ndez-Gonz\u00e1lez, JF, Rold\u00e1n Hern\u00e1ndez, CA, Mart\u00edn, ML, Mor\u00e1n, A., Garc\u00eda-Domingo, M., &amp; Garc\u00eda-Pedraza, Jos\u00e9 \u00c1ngel (2025). Influence of sex on serotonergic modulation of vascular noradrenergic drive in rats. British Journal of Pharmacology, 182 (4), 1025 &#8211; 1037. https:\/\/doi.org\/10.1111\/bph.17380.   <\/p>\n\n<p><a href=\"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bph.17380\">https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bph.17380<\/a><\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>The IBSAL<\/strong><\/p>\n\n<p>The Institute of Biomedical Research of Salamanca (IBSAL) was established on March 21, 2011 through an agreement signed by the Ministry of Health of the Regional Government of Castilla y Le\u00f3n and the University of Salamanca, which was joined in February 2012 by the Spanish National Research Council (CSIC). It integrates and coordinates the biosanitary research carried out at the University Hospital of Salamanca, the Primary Care Management of Salamanca and the biosanitary area of the University of Salamanca, including the Institute of Neurosciences of Castilla y Le\u00f3n and the Institute of Molecular and Cellular Biology of Cancer. <\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p>Its scientific activity is structured in six areas, with a total of 84 research groups: Cancer (23 groups); Cardiovascular, Renal and Respiratory (11); Neurosciences (12); Infectious, Inflammatory and Metabolic Diseases (17); Gene and Cell Therapy and Transplants (6) and Primary Care, Public Health and Pharmacology (15).<\/p>\n\n<div style=\"height:25px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n<p><strong>More information and contact:<\/strong><br\/><strong><a href=\"mailto:comunicacion@ibsal.es\">comunicacion@ibsal.es<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Cardiovascular Pharmacology Group, coordinated by M\u00f3nica Garc\u00eda Domingo, has demonstrated that the serotonergic system contributes differently in female and male rats when it comes to regulating vascular function, which [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":8266,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_tribe_ticket_capacity":"0","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[238],"tags":[246],"class_list":["post-8729","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-cardiology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v20.12 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors. | IBSAL<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors.\" \/>\n<meta property=\"og:description\" content=\"The Cardiovascular Pharmacology Group, coordinated by M\u00f3nica Garc\u00eda Domingo, has demonstrated that the serotonergic system contributes differently in female and male rats when it comes to regulating vascular function, which [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/\" \/>\n<meta property=\"og:site_name\" content=\"IBSAL\" \/>\n<meta property=\"article:published_time\" content=\"2025-03-18T11:18:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-03-18T12:12:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Sergi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sergi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/\"},\"author\":{\"name\":\"Sergi\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\"},\"headline\":\"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors.\",\"datePublished\":\"2025-03-18T11:18:00+00:00\",\"dateModified\":\"2025-03-18T12:12:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/\"},\"wordCount\":1339,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg\",\"keywords\":[\"Cardiology\"],\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/\",\"name\":\"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors. | IBSAL\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg\",\"datePublished\":\"2025-03-18T11:18:00+00:00\",\"dateModified\":\"2025-03-18T12:12:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg\",\"contentUrl\":\"https:\\\/\\\/ibsal.es\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibsal.es\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ibsal.es\\\/en\\\/\",\"name\":\"IBSAL\",\"description\":\"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n\",\"alternateName\":\"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibsal.es\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ibsal.es\\\/en\\\/#\\\/schema\\\/person\\\/34ba5672452d5f86b117e6cb49a6bb97\",\"name\":\"Sergi\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g\",\"caption\":\"Sergi\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors. | IBSAL","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/","og_locale":"en_US","og_type":"article","og_title":"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors.","og_description":"The Cardiovascular Pharmacology Group, coordinated by M\u00f3nica Garc\u00eda Domingo, has demonstrated that the serotonergic system contributes differently in female and male rats when it comes to regulating vascular function, which [&hellip;]","og_url":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/","og_site_name":"IBSAL","article_published_time":"2025-03-18T11:18:00+00:00","article_modified_time":"2025-03-18T12:12:21+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg","type":"image\/jpeg"}],"author":"Sergi","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Sergi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/#article","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/"},"author":{"name":"Sergi","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97"},"headline":"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors.","datePublished":"2025-03-18T11:18:00+00:00","dateModified":"2025-03-18T12:12:21+00:00","mainEntityOfPage":{"@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/"},"wordCount":1339,"commentCount":0,"image":{"@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg","keywords":["Cardiology"],"articleSection":["News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/","url":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/","name":"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors. | IBSAL","isPartOf":{"@id":"https:\/\/ibsal.es\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/#primaryimage"},"image":{"@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/#primaryimage"},"thumbnailUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg","datePublished":"2025-03-18T11:18:00+00:00","dateModified":"2025-03-18T12:12:21+00:00","author":{"@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97"},"breadcrumb":{"@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/#primaryimage","url":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg","contentUrl":"https:\/\/ibsal.es\/wp-content\/uploads\/2025\/03\/IBSAL-Farmacologia-EnfermedadCardioivascular-2-1-scaled-e1741851123219.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/ibsal.es\/en\/a-study-by-ibsal-and-usal-opens-new-therapeutic-avenues-to-improve-the-treatment-of-cardiovascular-disease-in-women-through-serotonin-receptors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibsal.es\/en\/"},{"@type":"ListItem","position":2,"name":"A study by IBSAL and USAL opens new therapeutic avenues to improve the treatment of cardiovascular disease in women through serotonin receptors."}]},{"@type":"WebSite","@id":"https:\/\/ibsal.es\/en\/#website","url":"https:\/\/ibsal.es\/en\/","name":"IBSAL","description":"Benchmarks in translational research in biomedicine in Castilla y Le\u00f3n","alternateName":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibsal.es\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ibsal.es\/en\/#\/schema\/person\/34ba5672452d5f86b117e6cb49a6bb97","name":"Sergi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/528ac3b73275e0b7aaacef0c293ace2a4935f7e6f58f8b31465b2faf9ae5ed56?s=96&d=mm&r=g","caption":"Sergi"}}]}},"_links":{"self":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/8729","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/comments?post=8729"}],"version-history":[{"count":0,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/posts\/8729\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media\/8266"}],"wp:attachment":[{"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/media?parent=8729"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/categories?post=8729"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ibsal.es\/en\/wp-json\/wp\/v2\/tags?post=8729"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}